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Abstract: Erythropoiesis is a rapidly evolving research arena and several mechanistic insights 
show therapeutic promise. In contrast with the rapid advance of mechanistic science, optimal 
management of anemia in patients with chronic kidney disease remains a difficult and polarizing 
issue. Although several large hemoglobin target trials have been performed, optimal treatment 
targets remain elusive, because none of the large trials to date have unequivocally identified 
differences in primary outcome rates or death rates, and because other reported outcomes indi-
cate the potential for harm (rates of stroke, early requirement for dialysis, and vascular access 
thrombosis) and benefit (reductions in transfusion requirements and fatigue).
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Introduction
Anemia is a typical feature of chronic kidney disease (CKD). In many countries, CKD 
is the commonest cause of anemia after that accounted for by iron, vitamin B12, and 
folate deficiencies, overt hemolysis, and ongoing bleeding. Although loss of renal 
erythropoietin production has traditionally been advanced as an explanation, there 
has been a gradual realization that other forces may be contributory. Although this is 
a nascent field, abnormal oxygen-sensing mechanisms and resistance to erythropoi-
etin may be a predominant issue in a sizeable proportion of patients with advanced 
CKD. This insight, which, as with many other conditions of relative hormonal defi-
ciency, has been slow to embed itself in clinical consciousness, and has considerable 
  implications. It suggests, for example, that greater efforts are needed to delineate the 
presence and causes of erythropoietin resistance when CKD and anemia intersect, 
both within individual patients and as part of the broader agenda for future research 
initiatives. A practical offshoot of this realization may be that anemia treatment 
algorithms predicated entirely on ever increasing doses of erythropoiesis-stimulating 
agents (ESAs) that ignore the issue of ESA resistance may not be optimal. Despite 
a profusion of mechanistic and therapeutic insights, treatment of anemia may be the 
singlemost controversial aspect of CKD management.
Somewhat tongue in cheek, as bigger and better randomized trials come and go, 
the notion that optimal indisputable anemia treatment strategies will become clear 
seems to recede ever further into the distance. Without wishing to diminish their 
potential importance, iron management protocols will not be considered in this article 
for space reasons and because, to date, randomized trials have focused completely 
on hemoglobin response, without meaningful consideration of differential effects on Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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conventional “hard” outcomes, including cardiovascular 
events, infectious events, and death. Similarly, epoetins that 
are considered biosimilar to epoetin alfa and beta will not be 
discussed here. The aspects considered in this review include 
the basic mechanistic constructs that underpin the bulk of 
current therapeutic development of ESAs, newer ESAs, 
hemoglobin target trials in CKD, and finally, some discussion 
about the implications of resistance to ESAs.
Erythropoietin: mechanistic 
constructs
Circulating erythropoietin consists of 165 amino acids in 
a single strand with two disulfide bonds and four carbohy-
drate chains, three of which are N-linked and one of which 
is O-linked.1 Plasma levels are inversely related to oxygen 
content; the half-life is 2–13 hours and metabolism takes 
place in the kidney, liver, and bone marrow. Ultimately, 
less than 10% of circulating erythropoietin is excreted by 
the kidneys.2–4
Although current understanding is incomplete, it is 
evident that erythropoietin gene (EPO) expression is tightly 
regulated by stimulators, including hypoxia-inducible tran-
scription factors (HIF) and hepatocyte nuclear factor 4α, and 
by inhibitors, including nuclear factor kappa B and GATA2.5 
HIF1, a key regulator of erythropoietin transcription, also 
regulates transcription of several other genes induced by 
hypoxia, including those for glycolytic enzymes, platelet-
derived growth factor, and vascular endothelial growth 
  factor.6 HIF1 binds to a hypoxia-response element residing 
on the 3´-flanking region of EPO.7 In the presence of hypoxia, 
HIF1 levels increase and the hypoxia-responsive genes 
become upregulated. In contrast, in the absence of hypoxia, 
the oxygen-sensitive HIF1α subunit is hydroxylated by prolyl 
hydroxylase, and degraded in the proteasome; ultimately, 
downregulation of EPO and other hypoxia-responsive 
genes occur.8 In this cascade of events, inhibition of prolyl 
hydroxylase should result in tonic, hypoxia-independent 
upregulation of EPO, and possibly several other hypoxia-
responsive genes.9
Following translation of the EPO gene, three N-linked and 
one O-linked carbohydrate chains are added to   erythropoietin. 
These chains normally exhibit heterogeneity in terms of the 
type of carbohydrate moieties incorporated, chain lengths, 
and branching configuration.10,11 The number of sialic resi-
dues also varies between healthy individuals, and up to four 
residues can be found on each N-linked carbohydrate chain, 
while up to two residues can be found on the O-linked chain, 
and variability in sialic acid composition has implications for 
the overall electrical charge of circulating erythropoietin.12 
In turn, overall electrical charge has effects on the circu-
lating half-life of erythropoietin and interactions with the 
erythropoietin receptor; in general, greater sialic acid content 
correlates with longer and greater potency.13
While marrow-based red blood cell-producing cells 
are thought to express the highest density of erythropoi-
etin receptors, erythropoietin receptors have been found in 
tissues throughout the body, including the kidney, brain, 
heart, retina, muscle, and vascular endothelium.14–16 Ligand-
receptor interaction leads to conformational changes in the 
dimeric transmembrane erythropoietin receptor, conforma-
tional changes and phosphorylation of tightly-associated 
Janus kinase 2 molecules, followed by phosphorylation of 
tyrosine moieties in the cytoplasmic domain of the eryth-
ropoietin receptor.17 Ultimately, the intracellular portion of 
the erythropoietin receptor becomes a docking complex for 
proteins exhibiting Src homology 2 (SH2) domains. After 
docking, SH2-containing proteins are activated by Janus 
kinase 2-mediated tyrosine phosphorylation and rendered 
capable of activating nuclear genes involved in cell growth 
and differentiation, and prevention of apoptosis.18–22
Newer erythropoiesis-stimulating 
agents
Darbepoetin, with its five amino acid substitutions and 
two extra carbohydrate chains, can incorporate as many as 
22 sialic acid residues, in contrast with native erythropoietin, 
which can incorporate 14 residues.23 Because darbepoetin 
has a longer half-life than erythropoietin, of approximately 
one day or more, it was anticipated that darbepoetin could be 
efficacious with longer dose intervals than with epoetins.24,25 
Multicenter, randomized, controlled trials have shown that 
darbepoetin once every 1–2 weeks is as effective in terms of 
attained hemoglobin levels as epoetin 2–3 times per week.26–29 
While the possibility of extended dose intervals is attractive 
for a compound requiring parenteral administration, several 
questions remain. For example, comparisons of costs and 
savings for optimized dosing schedules of different ESAs 
would be very helpful for clinical decision-making. In terms 
of basic mechanistic biology, it is unknown whether the non-
erythroid effects of darbepoetin in humans are similar to those 
of epoetins. Given its non-native chemical composition, there 
is a surprising lack of clinical information about the immuno-
genicity of darbepoetin. However, it is noteworthy that pure 
red cell aplasia has been described with this agent.30
In continuous erythropoietin receptor activator (CERA), 
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Dovepress 
Dovepress
105
Anemia in chronic kidney disease
the erythropoietin molecule via amide bonds between the 
N-terminal amino group of alanine and the σ-amino groups 
of a lysine at position 45 or 52, through a succinimidyl 
butanoic acid linker. CERA has a molecular weight twice 
that of erythropoietin and a half-life of over five days.31,32 
Randomized controlled trials in patients with anemia and 
CKD show that CERA, administered every 2–4 weeks, is not 
inferior to conventional ESA therapy in terms of hemoglobin 
response.33–38 As with darbepoetin, comparative nonerythroid 
effects and accurate rates of associated pure red cell aplasia 
have not been quantified in humans.
Several other synthetic proteins, modified erythropoietin 
derivatives, and peptide-based erythropoietin receptor acti-
vators are also being researched. For example, CNTO 528, 
an antibody fusion protein with a hematopoietic peptide 
attached to an IgG1 base (a “mimetibody”) has a half-life 
of approximately six days and shows erythropoietic activity 
in healthy men.39,40
Small erythropoietin-emulating peptides that interact with 
the erythropoietin receptor are also under active   investigation. 
For example, peginesatide, which consists of two peptide 
chains linked by a pegylation chain, appears to be distinct 
from erythropoietin in terms of antigen-antibody cross 
reactivity.41 In a rat model of antierythropoietin antibody-
mediated pure red cell aplasia, peginesatide administration 
led to correction of anemia.42 Similar findings were observed 
in humans in an open-label, uncontrolled study in which 
peginesatide was administered subcutaneously to 14 CKD 
patients with erythropoietin antibody-mediated pure red cell 
aplasia.43 Long-term clinical trials of peginesatide involving 
approximately 2600 CKD patients have been completed, and 
detailed study reports are awaited with interest.44
Insights into the biological underpinnings of erythro-
poiesis have led to the identification of several nonpeptide-
based (and potentially orally administered) candidates for 
the treatment of anemia in patients with CKD and other 
chronic diseases. As described above, while inhibition of 
prolyl hydroxylase should lead to enhanced erythropoietin 
production, nonselective inhibition could have pervasive 
regulatory effects on many genes, both known and unknown. 
An interesting proof-of-concept study with the orally 
active prolyl hydroxylase inhibitor, FG-2216, was recently 
reported.45 A single dose of FG-2216 was administered to 
six healthy volunteers, six anephric hemodialysis patients 
receiving conventional ESA therapy, and six hemodialysis 
patients with kidneys receiving ESAs. Erythropoietin levels 
increased 12.7-fold, 14.5-fold, and 30.8-fold, respectively, 
in the three groups. Even though study numbers are small, 
the findings in the anephric group are especially notable,   
and suggest that abnormal oxygen sensing may be at least as 
important in the pathogenesis of renal anemia as inadequate 
erythropoietin production.
The biological mechanisms described above implicate 
many gene-based pathways for increasing erythropoietin 
levels. However, uncontrolled erythropoietin production 
might be anticipated with many approaches. One notable 
study in erythropoietin-deficient transgenic mice described 
an intuitive approach to normalizing hemoglobin levels 
without incurring polycythemia, ie, use of a vector that adds 
a hypoxia-response element which, in turn, controls EPO 
transcription.46
Hemoglobin targets
Optimal management of anemia in patients with CKD 
remains a troublesome issue. This section discusses issues 
related to methodology and interpretation of the large num-
ber of published trials that most heavily influence current 
  treatment. It is not intended to be a systematic review or meta-
analysis, in part because several of these have already been 
published, and in part because of a belief that even the best 
of the available trials are so intrinsically different that simple 
aggregation of findings may not be advisable. As shown 
in Table 1, five large (.500 subjects) clinical trials have 
been reported to date, ie, US Normal Hematocrit47 (USNH), 
Canadian European Normalization of Hemoglobin48 (CENH), 
Cardiovascular Risk Reduction by Early Anemia Treatment 
with Epoetin Beta49 (CREATE), Correction of Hemoglobin 
and Outcomes in Renal Insufficiency50 (CHOIR), and Trial 
to Reduce Cardiovascular Events with Aranesp Therapy51 
(TREAT), targeting comparatively unique subsets of ane-
mic CKD patients with a distinctly heterogeneous array of 
interventions.
Hemoglobin target trials are nothing if not quirky and 
problematic. They differ profoundly from placebo-controlled 
trials using identical-looking pills, and these differences can 
impede interpretation and comparability with other trials. 
For example, target allocations are often not concealed (as 
with CHOIR, CREATE, USNH), a strategy that may reduce 
logistical complexity, especially when drugs are adminis-
tered parenterally in nonfixed doses that are adapted to on-
treatment biological analytes like hemoglobin. Even trials 
attempting to hide target allocation tend to become unmasked 
over time for several potential reasons. Because patients 
with CKD typically have other serious comorbid illnesses, 
they often have hemoglobin levels routinely drawn at other 
specialty clinics. Hence, even the most stringent efforts at Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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masking treatment allocation are unlikely to be completely 
successful. As a result, outcome comparisons that involve 
subjectivity on the part of patients and site investigators have 
to be viewed as less than pristine.
Nonrandomly assigned treatments, like iron and addi-
tional antihypertensive agents, are usually expected follow-
ing randomization, and highly imbalanced co-interventions 
can make it difficult to unravel the mechanisms underlying 
differences in trial outcomes. Immediate or delayed inter-
vention (CREATE and TREAT) is another trial design that 
systematically adds nonrandom elements. In the delayed 
intervention or rescue arms, treatment is determined by non-
random elements (time or a decrease in hemoglobin below 
a critical threshold). While the trigger for this intervention 
may be specified in advance by a well described algorithm, 
it clearly is not controlled by a notional coin toss.
Hemoglobin targets and principal treatment strategies 
for the five large trials are shown in Table 1. Regarding the 
critical issue of masked treatment allocation, only TREAT 
was placebo-controlled. Of the other trials, CENH incorpo-
rated concealment of treatment targets from patients. While 
concealed treatment allocation is intuitively important for 
outcomes like quality of life, it may also be important for rat-
ing “hard” clinical events. For example, basic physiological 
tenets teach us that polycythemia can cause vascular throm-
bosis and profound anemia can cause cardiac decompensa-
tion; familiarity with the assigned target hemoglobin may 
influence site investigators when confronted with common 
diagnostic challenges in advanced CKD, such as distin-
guishing nonspecific chest pain from angina pectoris and 
extracellular fluid volume overload from true heart failure. 
Unfortunately, blinded event committees have no control 
over what is written in case record forms at the site level and 
cannot correct site-level biases.
It has been known from the earliest days of treatment that 
ESAs can increase blood pressure levels, so active tracking 
of blood pressure levels, ESA doses, and hemoglobin levels 
would seem to be a reasonable safety requirement in clinical 
trials of aggressive hemoglobin management strategies.52 
The CENH trial incorporated centrally controlled real-time 
monitoring procedures for hemoglobin, iron, and blood 
pressure levels, with treatment recommendations returned 
to study sites within days of measurement. In TREAT, a 
point-of-care device was used for rapid measurement of hemo-
globin levels, which were entered into an interactive voice-
response system to determine the next dose of darbepoetin.
Table 1, which summarizes the treatment algorithms 
used to achieve target, shows that heterogeneity between Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
109
Anemia in chronic kidney disease
the   studies was large, to the extent that no two studies were 
strictly comparable. Although CREATE, CHOIR, and 
TREAT all examined patients with CKD not requiring dialy-
sis, CREATE used a strategy of delayed intervention in one 
treatment arm, while CHOIR used a typical parallel-group 
design without a time-varying therapeutic intent, and TREAT 
used a bit of both, with placebo control and the possibility of 
delayed intervention if anemia became sufficiently severe. 
Aggressiveness of ESA dosing varied greatly, even among 
apparently similar patients. For example, both the active 
and the control groups in CHOIR received a substantial 
initial dose of epoetin (10,000 U), and it is doubtful if many 
practicing clinicians would begin treating epoetin-naïve 
patients with such a large dose, particularly in the 50% of 
patients for whom the objective was to maintain current 
hemoglobin levels.
With regard to primary outcomes, no two studies were 
identical, although all but CENH share common elements 
(Table 1). While many trials these days use composite primary 
outcomes, it is always worthwhile to reflect on the individual 
components and their implications. In CHOIR, the primary 
outcome was time to first episode of death, myocardial 
infarction, heart failure hospitalization (provided dialysis 
was not employed for treatment), and stroke, with dialysis as 
a censoring event. With this design, episodes of heart failure 
that are severe enough to require dialysis are ignored, while 
less severe episodes are counted; it is certainly unusual that 
less severe episodes would be more likely to be included in 
treatment comparisons than more severe episodes. With the 
composite outcome designs employed in these studies, the 
first event is counted, and subsequent outcomes are ignored in 
situations where individuals experience multiple components 
of the composite outcome. All things being equal, it seems 
intuitively obvious to posit that patients who develop all the 
components of a composite outcome might receive more 
weight in outcome analysis. Composite outcomes can never 
exclude the possibility that serious but unknown treatment-
related effects may exist. As a result, comparisons of death 
rates, in isolation, need full attention, irrespective of the 
reported primary outcomes.
Table 1 also summarizes the hemoglobin levels achieved 
in these five studies. There has long been concern that 
very rapid increases in hemoglobin may be detrimental; 
first-month hemoglobin increments in the active treatment 
arms were notably higher in TREAT and CHOIR. During 
the maintenance phase, while no study maintained targeted 
hemoglobin levels, statistical separation was clear. ESA doses 
differed widely between the studies, with much higher doses 
in CHOIR than in CREATE, and much higher doses in USNH 
than in CENH. In the nondialysis CKD studies, these differ-
ences may be related to study design, because all patients in 
CHOIR were treated with epoetin alfa 10,000 U/week for 
three weeks, which was five times the starting dose used 
in the early intervention arm of CREATE. Blood pressure 
levels were higher in the active treatment arms in CHOIR 
and CREATE. While blood pressure levels were similar in 
the other studies, more antihypertensive agents were used in 
the high-target arm of CENH.
On unadjusted analysis, CREATE, TREAT, and USNH 
showed no differences in the primary outcome rates, whereas 
primary outcome rates were higher in the high hemoglobin 
target arm of CHOIR. Not unexpectedly, Table 1 shows that 
significant differences in baseline characteristics were present 
in each study. Given that several of these differences could 
be clinically important, it seems worthwhile to scrutinize the 
strategies used to deal with this issue. Of the three trials exam-
ining cardiovascular outcomes and death, USNH reported 
a comparison of the primary outcome with adjustment for 
baseline variables in the original publication, and the findings 
were very similar with and without covariate adjustment.2 
With CHOIR, while the original publication did not report 
an adjusted comparison of primary outcomes, a regulatory 
study report filed at ClinicalTrials.gov shows adjustment for 
baseline obviated statistical significance, with a P value of 
0.111, as opposed to 0.03 in the unadjusted analysis.53 The 
contrast between unadjusted significance and adjusted non-
significance leads to difficulties with overall interpretation 
of treatment effects, because it is impossible to reject the 
hypothesis that imbalanced assignment of factors other than 
study interventions caused the disparity in primary outcome 
rates seen on unadjusted analysis. TREAT also exhibited 
substantial baseline differences. While classical covariate 
adjustment was not undertaken, hazards ratios were reported 
that incorporated the strata used to randomize patients in 
the study–study site, baseline level of proteinuria, and an 
investigator-designated history of cardiovascular disease.
Quality of life was a secondary outcome in all of these 
trials, and although findings in this regard would never be 
considered definitive by purists, the available sample sizes 
were large. In addition, only TREAT attempted to conceal 
treatment allocation completely from patients, site investiga-
tors, and outcome assessors, and of the others, only CENH 
concealed treatments from study subjects. While four of these 
trials formally reported quality of life comparisons, no two 
trials used identical arrays of instruments. Three of the trials, 
including those that incorporated patient blinding, reported Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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quality of life benefits, predominantly in domains related to 
fatigue and vitality. In contrast, CHOIR showed a potential 
loss of quality life with the higher hemoglobin target for 
the emotional subscale of the Short Form-36   instrument; 
findings were likely clouded by important imbalances in 
baseline characteristics and the nonreporting of timing of 
study assessments and dropout rates. Critically, when it 
comes to assessing risks and benefits, none of the studies 
attempted to determine what differences in quality of life 
scales meant to patients.
Two of the studies examined left ventricular dimensions 
and found that hemoglobin targets had no effect. Transfusion 
rates, reported by all studies except CHOIR, were 37%–60% 
lower with higher targets. While no study showed an irre-
futable effect on primary study outcomes, several showed 
differences in important nonprimary event rates or in indi-
vidual components of the primary composite outcomes. For 
example, in CREATE, the risk of renal replacement therapy 
was greater in the immediate intervention arm, in spite of 
similar rates of change in glomerular filtration rate, vascular 
access loss was greater with higher targets in USNH, and 
stroke was greater in CENH. In TREAT, stroke rates were 
higher in the darbepoetin arm; for outcomes not incorporated 
in the primary outcome, darbepoetin was associated with 
higher rates of venous and arterial thromboembolism and 
higher rates of cancer-related death in subjects with cancer 
at baseline, without being associated with death attributed to 
cancer in the overall population and overall cancer rates.
Even though only five trials are examined in detail here, 
noteworthy differences were present at each level considered, 
ie, enrollment criteria, interventions, primary outcomes 
selected, treatment concealment, success of randomization, 
and study findings. In the presence of such distinct hetero-
geneity, it is questionable whether attempting to generate 
aggregate findings is a reasonable approach. It seems appar-
ent that an ideal approach to treating anemia in patients with 
CKD remains to be identified, and, despite years of research, 
much more investigation is needed.
Resistance to ESAs
There is a substantial amount of literature relating declining 
hemoglobin levels to adverse outcomes, including death, in 
patients with CKD.54 In addition, resistance to ESA, typically 
defined by high ratios of ESA dose to hemoglobin levels, is 
also associated with adverse outcomes.55,56 Two hypotheses 
are compatible with these observations, and have disturb-
ingly different treatment implications, ie, sicker patients 
need higher doses to achieve a given hemoglobin target and, 
assuming for a given patient that a given hemoglobin target 
can be achieved with different doses of ESA, higher ESA 
doses are harmful. In this regard, a recent subgroup analysis 
of the TREAT trial provides valuable insights.57 By design, 
patients receiving ESAs were excluded and fixed initial 
darbepoetin doses were employed. This subgroup analysis 
examined subjects in the active treatment arm, and reported 
higher rates of both the composite cardiovascular endpoint 
and death in those with a lesser hemoglobin response. Many, 
including the author of this report, have tended to interpret 
these findings as raising concern about current target-based 
strategies for treating anemia in patients with CKD.57 It seems 
difficult to make claims for dose-related harm, given that 
doses were fixed, and it is plausible that this is a beautiful 
demonstration of patient-related factors being responsible 
for a connection between hemoglobin response and harm, 
at least in this study.
Conclusion
Unraveling the biology of erythropoiesis has identified many 
potential therapeutic targets. Sadly, the quality and quantity 
of clinical trial information available to guide ESA use do 
not permit confident statements about optimally efficacious, 
safe, and cost-effective therapeutic strategies. With our ever 
increasing insight into the biology of erythropoietin, it seems 
natural to question whether different ESAs might have dif-
ferent nonerythroid effects at doses and intervals resulting in 
similar hemoglobin trajectories. If this is the case, the drug 
evaluation and approval of ESAs will need to go far beyond 
the research reported to date.
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